Galmed Pharmaceuticals Ltd. (NasdaqCM: GLMD)
Health Care · Biotechnology · IL
$4.31
+0.01% today · -61.8% 1Y
Galmed Pharmaceuticals Ltd. (NasdaqCM: GLMD) operates in the Biotechnology industry within the Health Care sector. The company is valued at $3.55M and employs 6 people.
Over the last twelve months the share price has lost 61.8%, trading between 3.29 and 13.20.
Tweenvest scores Galmed Pharmaceuticals Ltd. across four factors: quality 27/100. Its strongest factor is quality.
GLMD price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $3.55M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -16.13
- Dividend yield
- —
- Beta (5Y)
- 0.68
- 52-week high
- $13.20
- 52-week low
- $3.29
- Avg volume (3M)
- —
- Shares outstanding
- 824.96K
- Employees
- 6
- Next earnings
- —
About Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company develops MyBiotics which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.
- ISIN
- IL0011313900
- Founded
- 2000
- Listed since
- Mar 12, 2014
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $265.79 | +0.48% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $442.24 | -0.36% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.77 | +1.38% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $552.85 | +0.96% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $833.56 | +0.61% |
| argenx SEENXTBR: ARGX | $64.17B | €879.20 | +1.74% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $158.83 | +14.36% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.